The day concluded with the Masters of the Universe panel where AcuFocus executive chairman Jim Mazzo led a discussion between Link and executives from Abbott Medical Optics, Alcon, Allergan, Bausch & Lomb, Carl Zeiss Meditec, and Johnson & Johnson Vision Care. Mazzo introduced the panel – and the notion of industry consolidation – with a clever take on the game Agar.io as laid out in the TV show, “House of Cards.”
00:55 – Do you play video games
02:00 – Ophthalmology Strategic Landscape 20 years ago.
02:13 – 15 years ago
02:34 – 10 years ago
02:45 – Today’s strategic landscape
04:04 – Ashley McEvoy on J&J’s diversification
04:54 – J&J “quite bullish on eye health.”
06:00 – Ludwin Monz on Zeiss’ interest in medtech and eye care.
07:54 – Mike Ball on how Alcon fights for resources within Novartis.
09:12 – Ball: “I do like the support we are getting from Novartis.”
10:00 – Tom Frinzi on AMO’s appetite for acquisition.
11:40 – Bill Meury: “We view Allergan as an eye care company.”
13:29 – Bill Link on the venture perspective of ophthalmology.
15:45 – Calvin Roberts, MD, B&L operates independently under Valeant Model
16:45 – Has consolidation hurt innovation?
19:45 – Frinzi: Has it really consolidated?
21:50 – Why doesn’t Wall Street cover ophthalmology?
24:33 – Buy to Grow? Build to Grow? Build to Buy? Bill Link on building new companies.
27:10 – Roberts: Let’s focus on what the big companies do well.
29:00 –Ball: “What I worry about is looking for technology that is complementary and gets us into new areas and gives us the opportunity to take some home run swings.” Points to relationship with Google.
29:30 – Frinzi: Abbott is a med device company but if presented with a drug-based solution AMO would consider it.
30:07 – McEvoy on how J&J evaluates innovation.
32:20 – How do large organization approach medtech opportunities and compete with smaller, more local organizations.
35:00 – To Mike Ball: What lessons did you carry from ophthalmology to Hospira? And when you came back what surprised you the most about how ophthalmology has or hasn’t change?
38:00 – Bill Meury says he’s “never seen” as strong a relationship as the one that exists in ophthalmology.
39:00 – Who has been in eye the longest? Zeiss vs. Bausch & Lomb?
40:00 – Monz – Innovation has been constant – and is growing – at Zeiss.
40:40 – McEvoy on how J&J can grow in ophthalmology.
42:00 – Roberts on how his perspective as an ophthalmologist plays into B&L strategy.
44:10 – To Frinzi, what lessons and strategies apply to both big and small companies?
46:40 – Link: I’m personally a little disappointed that Alcon was separated out (between pharma and device.
Jim Mazzo is the Executive Chairman and CEO for AcuFocus. AcuFocus specializes in presbyopia correction and is known for its revolutionary KAMRA inlay which was recently FDA approved.
Mr. Ball was CEO of Hospira from 2011-2015. At Hospira, a world leader in injectable pharmaceuticals and infusion devices, he successfully turned the company around and grew it by focusing on product and quality improvements, and expanding its global footprint.
Thomas Frinzi is Senior Vice President of Abbott’s vision business, which includes a broad ophthalmology portfolio across the areas of cataracts, refractive surgery (LASIK) and eye health products. Prior to joining Abbott, Mr. Frinzi held a number of leadership positions in ophthalmology and medical device companies.
William J. Link, PhD
Bill was Founder, Chairman and CEO of Chiron Vision, sold in 1997. Bill founded and served as President of American Medical Optics (AMO), sold in 1986.
Ashley McEvoy, Company Group Chairman, Johnson & Johnson Vision Care and Johnson & Johnson Diabetes Care Companies, is leading globally integrated businesses in large and growing healthcare spaces.
Mr. Meury joined Actavis in July 2014 as Executive Vice President, Commercial, North American Brands. Prior to joining Actavis, he served as Executive Vice President, Sales and Marketing, Forest Laboratories, Inc.
Ludwin Monz, PhD
Dr. Ludwin Monz has been President and CEO of Carl Zeiss Meditec AG since 2010 and was appointed a member of the Executive Board of the ZEISS group in 2014.
Calvin W. Roberts, MD
Calvin W. Roberts, MD, is Executive Vice President and the Chief Medical Officer at Bausch + Lomb. A specialist in cataract and refractive surgery, Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens.